BridgeBio Pharma Financial Ratios
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
65.35+0.31 (+0.48%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma ratio analysis
BridgeBio Pharma earned a net margin of -146.0% in FY 2025, up from -244.9% a year earlier. Gross margin was 95.8% compared with a median of 95.6% over the prior 4 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 29.84 | 23.58 | 706.43 | 14.47 | 34.54 | 1,017.17 | 83.49 | — | — |
| Price / book | — | — | — | — | — | 144.90 | 8.29 | — | — |
| Gross margin | 95.8% | 98.3% | 73.7% | 95.6% | 95.5% | — | — | — | — |
| Operating margin | -104.2% | -267.2% | -6,528.8% | -659.6% | -827.1% | -5,752.0% | -656.4% | — | — |
| Net margin | -146.0% | -244.9% | -7,021.9% | -624.2% | -841.2% | -6,127.9% | -711.5% | — | — |
| Free cash flow margin | -89.0% | -235.1% | -5,686.6% | -546.5% | -733.2% | -4,936.7% | -631.7% | — | — |
| Return on equity (ROE) | — | — | — | — | — | -872.9% | -70.7% | -53.8% | -51.1% |
| Return on assets (ROA) | -78.3% | -59.1% | -119.6% | -77.8% | -57.9% | -71.8% | -45.7% | -36.4% | — |
| Debt / equity | — | — | — | — | — | 1.62 | 0.22 | 0.17 | — |
| Current ratio | 2.77 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | — |
| Revenue growth | 126.3% | 2,285.3% | -88.0% | 11.4% | 745.1% | -79.7% | — | — | — |